Identification of amides as carboxylic acid surrogates for quinolizidinone-based M1 positive allosteric modulators

ACS Medicinal Chemistry Letters

Volumn 3, Issue 12, 2012, Pages 1070-1074

  Kuduk, Scott D ^a   Chang, Ronald K ^a   Greshock, Thomas J ^a   Ray, William J ^a   Ma, Lei ^a   Wittmann, Marion ^a   Seager, Matthew A ^a   Koeplinger, Kenneth A ^a   Thompson, Charles D ^a   Hartman, George D ^a   Bilodeau, Mark T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

carboxylic acid surrogates; positive allosteric modulators; quinolizidinone

Indexed keywords

AMIDE; CARBOXYLIC ACID DERIVATIVE; CYCLOHEXANE; MULTIDRUG RESISTANCE PROTEIN; MUSCARINIC M1 RECEPTOR; PYRAN; QUINOLIZIDINE DERIVATIVE; TRANSCRIPTION FACTOR ERG;

ALLOSTERISM; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; IC 50; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; STRUCTURE ACTIVITY RELATION;

EID: 84871223303     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300280g     Document Type: Article

References (19)

1. Bonner, T. I. The molecular basis of muscarinic acetylcholine receptor diversity Trends Neurosci. 1989, 12, 148-151
2. Bonner, T. I. Subtypes of muscarinic acetylcholine receptors Trends Pharmacol. Sci. 1989, 11-15
3. Levey, A. I. Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer disease Proc. Natl. Acad. Sci. 1996, 93, 13541-13546
4. Geula, C. Abnormalities of neural circuitry in Alzheimer's disease: Hippocampus and cortical innervation Neurology 1998, 51, 518-529
5. Langmead, C. J.; Watson, J.; Reavill, C. Muscarinic acetylcholine receptors as CNS drug targets Pharmacol. Ther. 2008, 117, 232-243
6. Bodick, N. C.; Offen, W. W.; Levey, A. I.; Cutler, N. R.; Gauthier, S. G.; Satlin, A.; Shannon, H. E.; Tollefson, G. D.; Rasumussen, K.; Bymaster, F. P.; Hurley, D. J.; Potter, W. Z.; Paul., S. M. Effects of Xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavorial symptoms in Alzheimer. Disease Arch. Neurol. 1997, 54, 465-473
7. Greenlee, W.; Clader, J.; Asbersom, T.; McCombie, S.; Ford, J.; Guzik, H.; Kozlowski, J.; Li, S.; Liu, C.; Lowe, D.; Vice, S.; Zhao, H.; Zhou, G.; Billard, W.; Binch, H.; Crosby, R.; Duffy, R.; Lachowicz, J.; Coffin, V.; Watkins, R.; Ruperto, V.; Strader, C.; Taylor, L.; Cox, K. Muscarinic agonists and antagonists in the treatment of Alzheimer's Disease Il Farmaco 2001, 56, 247-250
8. Conn, P. J.; Christopulos, A.; Lindsley, C. W. Allosteric modulators of GPCRs: A novel approach for the treatment of CNS. Disorders Nat. Rev. Drug Discovery 2009, 8, 41-54
9. 1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats J. Neurosci. 2008, 41, 10422-10433
10. 1 muscarinic acetylcholine receptor achieved by allosteric potentiation Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 15950-15955
11. Yang, F. V.; Shipe, W. D.; Bunda, J. L.; Wisnoski, D. D.; Zhao, Z.; Lindsley, C. W.; Ray, W. J.; Ma, L.; Wittmann, M.; Seager, M. W.; Koeplinger, K.; Thompson, C. D.; Hartman, G. D. Parallel synthesis of N -biaryl quinolone carboxylic acids as selective M1 positive allosteric modulators Bioorg. Med. Chem. Lett. 2010, 19, 531-535
12. Kuduk, S. D.; Di Marco, C. N.; Cofre, V.; Pitts, D. R.; Ray, W. J.; Ma, L.; Wittmann, M.; Seager, M.; Koeplinger, K. A.; Thompson, C. D.; Hartman, G. D.; Bilodeau, M. T. Pyridine containing M1 positive allosteric modulators with reduced plasma protein binding Bioorg. Med. Chem. Lett. 2010, 19, 657-660
13. 1 Positive Allosteric Modulators Bioorg. Med. Chem. Lett. 2010, 19, 1334-1337
14. 1 positive allosteric modulators Bioorg. Med. Chem. Lett. 2010, 19, 2533-2537
15. 1 positive allosteric modulators Bioorg. Med. Chem. Lett. 2010, 19, 2538-2541
16. 1 Allosteric Muscarinic Receptor Modulators ACS Med. Chem. Lett. 2010, 1, 263-267
17. 1 Allosteric Modulators: SAR in the Piperidine Series Bioorg. Med. Chem. Lett. 2011, 21, 1710-1713
18. Kuduk, S. D.; Chang, R. K.; Di Marco, C. N.; Pitts, D. R.; Greshock, T. J.; Ma, L.; Wittmann, M.; Seager, M.; Koeplinger, K. A.; Thompson, C. D.; Hartman, G. D.; Bilodeau, M. T.; Ray, W. J. Discovery of a Selective Allosteric M1 Receptor Modulator with Suitable Development Properties Based on a Quinolizidinone Carboxylic Acid Scaffold J. Med. Chem. 2011, 13, 4773-4780
19. For examples of noncarboxylic positive allosteric M1 modulators, see Reid, P. R.; Bridges, T. M.; Sheffler, D. A.; Cho, H. P.; Lewis, L. M.; Days, E.; Daniels, J. S.; Jones, C. K.; Niswender, C. M.; Weaver, C. D.; Conn, P. J.; Lindsley, C. W.; Wood, M. R. Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN Probe Bioorg. Med. Chem. Lett. 2011, 21, 2697-2701